Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Finding highlights new ways of treating inflammation disorders

A team led by scientists at The Scripps Research Institute (TSRI) has identified key signaling proteins in the inflammation process that contribute to the development of inflammatory diseases such as rheumatoid arthritis, psoriasis, sepsis and inflammatory bowel diseases.

11 Oct 2013

TSRI scientists identify set of compounds to treat multiple sclerosis in new way

Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.

10 Oct 2013

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Compugen Ltd., announced today that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

9 Oct 2013

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, describes a powerful new anti-inflammatory mechanism that could lead to the development of new oral medications for atherosclerosis and inflammatory bowel disorders (IBS).

7 Oct 2013

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

Investigators at The Feinstein Institute for Medical Research have discovered a protein in the human body that can trigger and mediate inflammation in patients suffering from hemorrhage and sepsis. The findings were published in the online version of Nature Medicine on October 6, 2013.

7 Oct 2013

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.

7 Oct 2013

J&J's Janssen Companies Launch A Trio Of Collaborations

...

3 Oct 2013

Roadmap of protein interactions may lead to new therapeutic approaches for type 2 diabetes

A team led by scientists at The Scripps Research Institute (TSRI) has created the first comprehensive roadmap of the protein interactions that enable cells in the pancreas to produce, store and secrete the hormone insulin.

1 Oct 2013

Pfizer Licenses Gliknik's Pooled IVIG In $25M+ Deal

...

30 Sep 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

Discovery could help develop new treatments for blood diseases

Researchers in Melbourne, Australia, have found that even our immune system is subject to performance enhancement, with our bodies giving immune cells the boost they need to ensure the best team is selected to fight infections.

24 Sep 2013

Abbvie, Ablynx Ink Up To $840M RA, SLE Collaboration

...

23 Sep 2013

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

Ablynx and AbbVie today announced that they have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

23 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

Parenting stress among caregivers of children with chronic illness: A systematic review

The extra demands on parents of chronically ill children cause stress that affects the whole family, according to a systematic review conducted by Case Western Reserve University researchers that also explored what factors in the child's care most contribute to the added strain.

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years.

18 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Finding highlights new ways of treating inflammation disorders

TSRI scientists identify set of compounds to treat multiple sclerosis in new way

Compugen drug candidate prevents autoimmune type I diabetes in animal model

Anti-inflammatory mechanism leads to development of oral medications for atherosclerosis, IBS

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

J&J's Janssen Companies Launch A Trio Of Collaborations

Roadmap of protein interactions may lead to new therapeutic approaches for type 2 diabetes

Pfizer Licenses Gliknik's Pooled IVIG In $25M+ Deal

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Abbvie, Galapagos Ink Up To $405M CF Collaboration

Abbvie, Galapagos Ink Up To $405M CF Collaboration

Discovery could help develop new treatments for blood diseases

Abbvie, Ablynx Ink Up To $840M RA, SLE Collaboration

Abbvie, Ablynx ink license agreement to develop anti-IL-6R Nanobody against inflammatory diseases

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Parenting stress among caregivers of children with chronic illness: A systematic review

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in